Clinical trial
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT07379827
Study timeline
Study start (actual)2026-02-26Date precision: day
Registry last updated2026-08-19
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Schizophreniaunresolved
Interventions
Sponsors & collaborators
Bristol-Myers Squibblead sponsor
Mapped research locations
HoustonTexas, United States5MiamiFlorida, United States4AnaheimCalifornia, United States2PhiladelphiaPennsylvania, United States1DallasTexas, United States1AtlantaGeorgia, United States1San AntonioTexas, United States1OrlandoFlorida, United States1Oklahoma CityOklahoma, United States1DetroitMichigan, United States1AustinTexas, United States1RochesterNew York, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07379827 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.